Avicanna Inc. (FRA:0NN)

Market Cap	16.80M
Revenue (ttm)	15.60M
Net Income (ttm)	-1.15M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,000
Average Volume	2,671
Open	0.1320
Previous Close	0.1260
Day's Range	0.1300 - 0.1320
52-Week Range	0.1220 - 0.2540
Beta	n/a
RSI	46.19
Earnings Date	Mar 31, 2026

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of de...

• Industry: Pharmaceutical Preparations
• Founded: 2016
• Employees: 87
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0NN

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.

Financial numbers in CAD